

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA188; Human growth hormone for treating growth failure in children (review of TA42)

This guidance was issued May 2010 with a review date of May 2013.

Background

At the GE meeting of 7 May 2013 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The guidance should be transferred to the 'static guidance list'.
Rationale for selecting this proposal	There is no new evidence that has the potential to lead to a change in the recommendations. Also, the marketing authorisations for the interventions have not changed, no new interventions have come to market since technology appraisal 188 was issued, and there have been no marked changes in the prices of the interventions.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	TA188 will be transferred to the 'static guidance list'
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Ipsen	Agree	We are happy with the approach proposed by NICE to move TA 188 to the static list of technology appraisals.	Comment noted.
Novo Nordisk	No comment	We do not have any further comments to add to those we submitted previously.	Comment noted.
Pfizer	Agree	Pfizer is in agreement with NICE's proposal to move NICE MTA TA188 to the static list for technology appraisals	Comment noted.
Lilly	Agree	We are not aware of any new evidence which would suggest that a review to this appraisal would be beneficial and agree with your proposal to transfer the original guidance to the static list.	Comment noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Ferring	Agree (with changes requested)	<p>In the GE proposal document provided by NICE, Appendix 2, page 9, the stated cost of treatment with Zomacton® does not mention that Zomacton® is available both as 4 mg and 10 mg vials, and that each dose is available with a needle-free administration device. Ferring Pharmaceuticals will request that the following information be added to the GE document, Appendix 2, for the cost of treatment with Zomacton®:</p> <p>Zomacton® 4-mg (12-unit) vial (with diluent) for use with ZomaJet® 2 Vision needle free device = £79.69.</p> <p>Zomacton® 10-mg (30-unit) vial (with diluent – needle free) for use with ZomaJet® Vision X needle free device = £199.23.</p> <p>Ferring Pharmaceuticals is not aware of any new relevant evidence for Zomacton® to propose any other change to the HTA assessment.</p>	<p>A published proposal paper cannot be amended retrospectively. Also, the information requested to be added is not essential for the review decision, and is made available by way of publishing this review decision.</p> <p>Comment noted.</p>

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Royal College of Nursing	Agree	<p>Nurses caring for children with growth failure were invited to review the proposal to move the guidance to the static list in view of the fact that there is currently no new evidence that is likely to have a material effect on the existing recommendations.</p> <p>In view of feedback received, the RCN agrees with the proposal to move the technology appraisal guidance: TA188 to the static list unless new evidence emerges.</p>	Comment noted.
Turner Syndrome Support Society	Agree	The Turner Syndrome Support Society agree with the recommendation to move the guidance to the static list.	Comment noted.
Medicines and Healthcare Products Regulatory Agency	No comment	We are not aware of any information that impinges on your proposal.	Comment noted.

No response received from:

<u>Manufacturers/sponsors</u> <ul style="list-style-type: none"> • Merck Serono (somatropin) • Sandoz (somatropin) 	<u>General</u> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales
--	--

Patient/carer groups

- Action for Children
- Action for Sick Children
- Afiya Trust
- Black Health Agency
- Child Growth Foundation
- Children's Society
- Equalities National Council
- Independent Age
- Muslim Council of Britain
- Muslim Health Network
- National Children's Bureau
- National Parent Partnership Network
- Pituitary Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- WellChild

Professional groups

- British Society for Paediatric Endocrinology & Diabetes
- Royal College of General Practitioners
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Endocrinology
- United Kingdom Clinical Pharmacy Association

- British National Formulary
- Care Quality Commission
- Commissioning Support Appraisals Service
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Public Health Wales NHS Trust
- Scottish Medicines Consortium

Comparator manufacturers

- None

Relevant research groups

- Cochrane Metabolic & Endocrine Disorders Group
- Health Research Authority
- MRC Clinical Trials Unit
- National Institute for Health Research

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

- None

<u>Others</u> <ul style="list-style-type: none">• Department of Health• NHS England• NHS Medway CCG• NHS Wokingham CCG• Welsh Government	<u>Associated Public Health Groups</u> <ul style="list-style-type: none">• None
--	---

GE paper sign-off: Elisabeth George, Associate Director – Technology Appraisals Programme

Contributors to this paper:

Technical Lead: Linda Landells

Project Manager: Andrew Kenyon

1 July 2013